The failure to achieve full rejection of the tumor in the cohort expressing PDL1 may be a consequence of reduced proliferation or indicative of redundant but inefficient mechanisms mediating inhibition of CAR T activity through PD1 in the absence of SHP2. The gene discussed is PTPN11; the disease is neoplasm.